1. Home
  2. WIA vs MOLN Comparison

WIA vs MOLN Comparison

Compare WIA & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Income Fund

WIA

Western Asset Inflation-Linked Income Fund

HOLD

Current Price

$8.25

Market Cap

197.8M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.33

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WIA
MOLN
Founded
2003
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
197.8M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WIA
MOLN
Price
$8.25
$4.33
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
39.2K
5.2K
Earning Date
01-01-0001
10-30-2025
Dividend Yield
12.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,000.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.56
$3.36
52 Week High
$8.91
$5.91

Technical Indicators

Market Signals
Indicator
WIA
MOLN
Relative Strength Index (RSI) 39.17 53.51
Support Level $8.24 $4.13
Resistance Level $8.29 $4.57
Average True Range (ATR) 0.06 0.14
MACD -0.00 -0.00
Stochastic Oscillator 25.00 54.03

Price Performance

Historical Comparison
WIA
MOLN

About WIA Western Asset Inflation-Linked Income Fund

Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: